See more : King Resources, Inc. (KRFG) Income Statement Analysis – Financial Results
Complete financial analysis of Alpha Tau Medical Ltd. (DRTS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Alpha Tau Medical Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Wee Hur Holdings Ltd. (E3B.SI) Income Statement Analysis – Financial Results
- Motherson Sumi Wiring India Limited (MSUMI.NS) Income Statement Analysis – Financial Results
- Foxtons Group plc (FTXGF) Income Statement Analysis – Financial Results
- XYMAX REIT Investment Corporation (3488.T) Income Statement Analysis – Financial Results
- DMG MORI AKTIENGESELLSCHAFT (GIL.DE) Income Statement Analysis – Financial Results
Alpha Tau Medical Ltd. (DRTS)
About Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.07M | 979.00K | 776.00K | 86.00K | 0.00 |
| Gross Profit | -1.07M | -979.00K | -776.00K | -86.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 26.42M | 20.89M | 11.45M | 7.54M | 6.64M |
| General & Administrative | 7.33M | 10.27M | 1.86M | 1.41M | 977.00K |
| Selling & Marketing | 1.92M | 974.00K | 482.00K | 288.00K | 397.00K |
| SG&A | 9.26M | 11.25M | 2.34M | 1.70M | 1.37M |
| Other Expenses | -72.20M | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | -35.68M | 32.14M | 13.79M | 9.24M | 8.01M |
| Cost & Expenses | -35.68M | 32.14M | 13.79M | 9.24M | 8.01M |
| Interest Income | 4.76M | 1.79M | 211.00K | 613.00K | 776.00K |
| Interest Expense | 39.00K | 1.77M | 13.27M | 217.00K | 0.00 |
| Depreciation & Amortization | 1.07M | 979.00K | 776.00K | 86.00K | 66.00K |
| EBITDA | -28.03M | -32.74M | -13.22M | -9.16M | -7.94M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 35.68M | -32.14M | -13.79M | -9.24M | -8.01M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -64.82M | -1.61M | -13.47M | 520.00K | -308.00K |
| Income Before Tax | -29.14M | -33.74M | -27.26M | -8.72M | -8.32M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 16.00K | 20.00K | 7.00K | 158.00K | 146.00K |
| Net Income | -29.16M | -33.76M | -27.27M | -8.88M | -8.46M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.42 | -0.53 | -0.67 | -0.22 | -0.13 |
| EPS Diluted | -0.42 | -0.53 | -0.67 | -0.22 | -0.13 |
| Weighted Avg Shares Out | 69.38M | 63.53M | 40.53M | 40.43M | 67.62M |
| Weighted Avg Shares Out (Dil) | 69.38M | 63.53M | 40.53M | 40.43M | 67.62M |
Alpha Tau Medical to Present at the Emerging Growth Conference on August 9th, 2023
JERUSALEM, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that Raphi Levy, Chief Financial Officer, will present at...
Alpha Tau Medical to Participate in June Investor Conferences
JERUSALEM, May 24, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that management will participate in the following investor conferences.
Should You Buy Alpha Tau Medical (DRTS) Ahead of Earnings?
Alpha Tau Medical (DRTS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Alpha Tau Medical to Present at Guggenheim Radiopharmaceuticals Day
JERUSALEM, May 03, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that Raphi Levy, Chief Financial Officer, will take part...
OurCrowd Launches $200 Million Global Health Equity Fund in collaboration with the WHO Foundation at the Clinton Global Initiative
NEW YORK--(BUSINESS WIRE)--OurCrowd, a leading global venture firm, announced today the launch of a Global Health Equity Fund (GHEF) in collaboration with the WHO Foundation. The news was shared at the first major Clinton Global Initiative meeting convened since 2016,...
4 Top Biotech Stocks To Watch Today
As the industry continues to make new discoveries, could biotech stocks be in focus?
Alpha Tau: Treating Cancer With Precision Alpha Radiation
Alpha Tau Medical's proprietary Alpha DaRT device safely delivers alpha radiation with localized precision to treat cancers.
12 Stocks Halted On A Circuit Breaker This Week
A circuit breaker is an automatic, temporary trading halt on certain securities when the underlying stock is experiencing times of high volatility. It is a measure put in place to help restore, and bring order to the markets.
Source: https://incomestatements.info
Category: Stock Reports